Connect with us

Hi, what are you looking for?

Daily Market SolutionDaily Market Solution

Investing

Eyenovia to end eye drug study, cut 50% of its workforce

(Reuters) -Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness and cut about 50% of its workforce.

Shares of the company were down nearly 70% at close of trading on Friday.

The drug, a low-dose atropine, was being tested with the company’s experimental drug-delivery device, Optejet, as a potential treatment for progressive myopia in children aged between 3 and 12.

An independent committee reviewed the safety and efficacy data from 252 trial participants and found that the rate of myopia progression was not significantly different between the treatment arm and placebo.

All doses of the drug appeared to be well-tolerated with “mild and infrequent” side-effects, the company said.

Optejet delivers the drug in microdoses and reduces chances of overdosing compared to conventional eyedroppers, according to the company.

The drug developer said it plans to review the data more thoroughly and evaluate strategic options, including a business combination, reverse merger and/or sale of assets.

The company said its remaining staff will be focused on the development of the second generation of Optejet.

Earlier this year, Eyenovia (NASDAQ:EYEN) had gained U.S. approval for its eye drops to reduce inflammation and pain in patients who have undergone eye surgery.

The company also markets a pupil-dilating spray, Mydcombi, for use with Optejet during eye examinations.

This post appeared first on investing.com







    You May Also Like

    Editor's Pick

    Extremist supporters of former president Donald Trump are lashing out online against Usha Vance, the wife of Trump’s running mate, Sen. J.D. Vance (R-Ohio),...

    Investing

    Overview Energy Fuels (TSX:EFR,NYSE:UUUU) has been the largest producer of uranium in the United States and an emerging producer of rare earth elements (REEs)....

    Investing

    Investor Insight Silver prices breached $30/oz in the second half of May 2024 as investor demand drove prices to their highest in more than...

    Investing

    Overview Flynn Gold Limited (ASX: FG1) is an Australian mineral exploration company with a portfolio of projects in Tasmania and Western Australia. Tasmania is...

    Disclaimer: Dailymarketsolution.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 dailymarketsolution.com